# Genotype-guided Versus Standard for Warfarin Dosing

> **NCT03479684** · NA · COMPLETED · sponsor: **China National Center for Cardiovascular Diseases** · enrollment: 560 (actual)

## Conditions studied

- Atrial Fibrillation
- Valvular Heart Disease

## Interventions

- **OTHER:** Gene-directed dosage of warfarin
- **OTHER:** standard dosage of warfarin

## Key facts

- **NCT ID:** NCT03479684
- **Lead sponsor:** China National Center for Cardiovascular Diseases
- **Sponsor class:** OTHER_GOV
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01-01
- **Primary completion:** 2021-12-31
- **Final completion:** 2021-12-31
- **Target enrollment:** 560 (ACTUAL)
- **Last updated:** 2022-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03479684

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03479684, "Genotype-guided Versus Standard for Warfarin Dosing". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03479684. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*